7585-39-9

Basic information

• Product Name: BETA-CYCLODEXTRIN
• Synonyms: BETA BYCLODEXTRIN;BW 7;CavaMax W 7;CAVAMAX W7 PharMa;Celdex B 100;Celdex B 100H;Celdex B 100z;Celdex N
• CAS NO: 7585-39-9
• Molecular Formula: C42H70O35
• Molecular Weight: 1134.98
• EINECS: 231-493-2
• Product Categories: Inhibitors;Industrial/Fine Chemicals;Biochemistry;Cyclodextrins;Functional Materials;Macrocycles for Host-Guest Chemistry;Oligosaccharides;Sugars;Dextrins、Sugar & Carbohydrates;Cosmetic Ingredients & Chemicals
• Mol File: 7585-39-9.mol
• Article Data: 79

Chemical Properties

• Melting Point: >260 °C (dec.)(lit.)
• Boiling Point: 844.96°C (rough estimate)
• Flash Point: 908.5oC
• Appearance: white/powder
• Density: 1.2296 (rough estimate)
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.7500 (estimate)
• Storage Temp.: +15C to +30C
• Solubility: 1 M NaOH: 50 mg/mL
• PKA: 11.73±0.70(Predicted)
• Water Solubility: Soluble in water and ammonium hydroxide.
• Stability: Stable. Incompatible with strong oxidizing agents.
• Merck: 14,2718
• BRN: 78623
• CAS DataBase Reference: BETA-CYCLODEXTRIN(CAS DataBase Reference)
• NIST Chemistry Reference: BETA-CYCLODEXTRIN(7585-39-9)
• EPA Substance Registry System: BETA-CYCLODEXTRIN(7585-39-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-20
• Safety Statements: 26-36-24/25
• WGK Germany: 2
• RTECS: GU2293000
• TSCA: Yes
• Hazardous Substances Data: 7585-39-9(Hazardous Substances Data)

Usage

Description

Cyclodextrins refer to a family of compounds consisting of sugar molecules bound together in ring (cyclic oligosaccharides). It is produced from starch through enzymatic conversion. Beta-cyclodextrin is the 7-membered sugar ring molecular form of cyclodextrin. Cyclodextrin has various applications. In the pharmaceutical industry, it can be used as complexing agents for increasing the solubility of poorly soluble drug as well as increasing their bioavailability and stability. It can also alleviate the gastrointestinal drug irritation, and prevent drug-drug and drug-excipient interactions. It can also be used in food, pharmaceutical, drug delivery, and chemical industries, as well as agriculture and environmental engineering.

References

https://en.wikipedia.org/wiki/Cyclodextrin https://notendur.hi.is/thorstlo/general.pdf

Chemical Properties

Different sources of media describe the Chemical Properties of 7585-39-9 differently. You can refer to the following data:
1. white powder
2. Cyclodextrins occur as white, practically odorless, fine crystalline powders, having a slightly sweet taste. Some cyclodextrin derivatives occur as amorphous powders.
3. A biennial herbaceous plant very common in Europe, Asia, Africa and the United States, it has a tapering fleshy root, furrowed stem, finely cut feathery leaves, umbels of small flower heads in midsummer, and capsules containing two curved narrow seeds. The plant grows to about 60 cm and it blooms from May to July. The part used is the fruit, containing approximately 15% of fixed oils and 3 to 7% of essential oil. Caraway has a warm, biting flavor with a strong, fatty, harsh undernote.
4. beta Cyclodextrin is a virtually odorless, slightly sweet-tasting, white or almost white crystalline solid or fine powder.

Occurrence

A derivative of naturally occurring starch.

Uses

Different sources of media describe the Uses of 7585-39-9 differently. You can refer to the following data:
1. Use to solubilize non-polar compounds such as fatty acids, lipids and cholesterol. Reported useful for the selective precipitation of enantiomeric, positional or structural isomersβ-Cyclodextrin is used with dansyl chloride to form water-soluble complexes for fluorescent labeling of proteins. It is an active ingredient of household odor eliminator. It is also used in personal care products like toothpastes, skin creams and dusting powders. It finds applications in the cosmetic industry for products like detergents and perfumes for the controlled release of fragrances. Further, it is used to produce HPLC columns allowing chiral enantiomers separation. In addition to this, it is used to decrease the level of cholesterol in milk fat.
2. β-Cyclodextrin is a cyclic oligosaccharide produced from starch via enzymatic conversion. β-Cyclodextrin is commonly used to produce HPLC columns allowing chiral enantiomers separation.

Production Methods

Cyclodextrins are manufactured by the enzymatic degradation of starch using specialized bacteria. For example, β-cyclodextrin is produced by the action of the enzyme cyclodextrin glucosyltransferase upon starch or a starch hydrolysate. An organic solvent is used to direct the reaction that produces β-cyclodextrin, and to prevent the growth of microorganisms during the enzymatic reaction. The insoluble complex of β-cyclodextrin and organic solvent is separated from the noncyclic starch, and the organic solvent is removed in vacuo so that less than 1 ppm of solvent remains in the β-cyclodextrin. The β-cyclodextrin is then carbon treated and crystallized from water, dried, and collected.

Preparation

Usually produced commercially from Bacillus macerans or B. circulans fermentation of starch or starch hydrolysate.

Essential oil composition

In addition to carvone, the oil contains d-limonene, carveol, diacetyl furfural, methyl alcohol, acetic aldehyde and other substances. Caraway oil consists of 3.5 to 7% volatile and fatty oils; resin, sugar, tannin, mucilage.

Taste threshold values

Reported to have a taste threshold value lower than that of sucrose with a detection level of 3.9 to 27 ppm and a recognition level of 11 to 52 ppm

General Description

Beta-Cyclodextrin is the most abundant and cheap cyclic oligosaccharide that forms inclusion complexes with several drug molecules. Its main application is in tablet and capsule formulations.Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

Flammability and Explosibility

Nonflammable

Pharmaceutical Applications

Cyclodextrins are ‘bucketlike’ or ‘conelike’ toroid molecules, with a rigid structure and a central cavity, the size of which varies according to the cyclodextrin type. The internal surface of the cavity is hydrophobic and the outside of the torus is hydrophilic; this is due to the arrangement of hydroxyl groups within the molecule. This arrangement permits the cyclodextrin to accommodate a guest molecule within the cavity, forming an inclusion complex.Cyclodextrins may be used to form inclusion complexes with a variety of drug molecules, resulting primarily in improvements to dissolution and bioavailability owing to enhanced solubility and improved chemical and physical stability.Cyclodextrin inclusion complexes have also been used to mask the unpleasant taste of active materials and to convert a liquid substance into a solid material. b-Cyclodextrin is the most commonly used cyclodextrin, although it is the least soluble. It is the least expensive cyclodextrin; is commercially available from a number of sources; and is able to form inclusion complexes with a number of molecules of pharmaceutical interest. However, b-cyclodextrin is nephrotoxic and should not be used in parenteral formulations. b-Cyclodextrin is primarily used in tablet and capsule formulations. In oral tablet formulations, b-cyclodextrin may be used in both wet-granulation and direct-compression processes. The physical properties of b-cyclodextrin vary depending on the manufacturer. However, b-cyclodextrin tends to possess poor flow properties and requiresalubricant,such as 0.1% w/w magnesium stearate,when it is directly compressed.In parenteral formulations, cyclodextrins have been used to produce stable and soluble preparations of drugs that would otherwise have been formulated using a nonaqueous solvent. In eye drop formulations, cyclodextrins form water-soluble complexes with lipophilic drugs such as corticosteroids. They have been shown to increase the water solubility of the drug; to enhance drug absorption into the eye; to improve aqueous stability; and to reduce local irritation.Cyclodextrins have also been used in the formulation of solutions,suppositories, and cosmetics.

Biochem/physiol Actions

β-Cyclodextrin is the cyclic α heptamer of glucose. It acts as a host to form inclusion compounds with the guests including derivatives of benzene, cyclohexane, adamantane, other alicyclic guests, and also inorganic molecules or ions. It is generally used to solubilize non-polar compounds such a fatty acids, lipids and cholesterol.

Safety

Cyclodextrins are starch derivatives and are mainly used in oral and parenteral pharmaceutical formulations. They are also used in topical and ophthalmic formulations. Cyclodextrins are also used in cosmetics and food products, and are generally regarded as essentially nontoxic and nonirritant materials. However, when administered parenterally, β-cyclodextrin is not metabolized but accumulates in the kidneys as insoluble cholesterol complexes, resulting in severe nephrotoxicity. Cyclodextrin administered orally is metabolized by microflora in the colon, forming the metabolites maltodextrin, maltose, and glucose; these are themselves further metabolized before being finally excreted as carbon dioxide and water. Although a study published in 1957 suggested that orally administered cyclodextrins were highly toxic, more recent animal toxicity studies in rats and dogs have shown this not to be the case, and cyclodextrins are now approved for use in food products and orally administered pharmaceuticals in a number of countries. Cyclodextrins are not irritant to the skin and eyes, or upon inhalation. There is also no evidence to suggest that cyclodextrins are mutagenic or teratogenic. β-Cyclodextrin LD50 (mouse, IP): 0.33 g/kg(16) LD50 (mouse, SC): 0.41 g/kg LD50 (rat, IP): 0.36 g/kg LD50 (rat, IV): 1.0 g/kg LD50 (rat, oral): 18.8 g/kg LD50 (rat, SC): 3.7 g/kg

storage

Cyclodextrins should be stored in a tightly sealed container, in a cool, dry place.Cyclodextrins are stable in the solid state if protected from high humidity.

Purification Methods

Recrystallise β-cyclodextrin from water and dry it for 12hours in a vacuum at 110o, or 24hours in a vacuum at 70o. The purity is assessed by TLC on cellulose containing a fluorescent indicator. [Taguchi, J Am Chem Soc 108 2705 1986, Tabushi et al. J Am Chem Soc 108 4514 1986, Orstam & Ross J Phys Chem 91 2739 1987.] [Beilstein 19 IV 6287, 19/12 V 801.]

Regulatory Status

Included in the FDA Inactive Ingredients Database: α-cyclodextrin (injection preparations); β-cyclodextrin (oral tablets, topical gels); γ-cyclodextrin (IV injections). Included in the Canadian List of Acceptable Non-medicinal Ingredients (stabilizing agent; solubilizing agent ); and in oral and rectal pharmaceutical formulations licensed in Europe, Japan, and the USA.

InChI:InChI=1/C42H70O35.H2O/c43-1-8-29-15(50)22(57)36(64-8)72-30-9(2-44)66-38(24(59)17(30)52)74-32-11(4-46)68-40(26(61)19(32)54)76-34-13(6-48)70-42(28(63)21(34)56)77-35-14(7-49)69-41(27(62)20(35)55)75-33-12(5-47)67-39(25(60)18(33)53)73-31-10(3-45)65-37(71-29)23(58)16(31)51;/h8-63H,1-7H2;1H2

Synthetic route

6A,6B,6D,6E-tetradeoxy-2A,2B,2C,2D,2E,2F,2G,3A,3B,3C,3D,3E,3F,3G,6C,6F,6G-heptadeca-O-benzyl-β-cyclodextrin → β‐cyclodextrin (7585-39-9)

Conditions	Yield
With palladium 10% on activated carbon; hydrogen In tetrahydrofuran; water regioselective reaction;	100%

mono-6-deoxy-6-(p-tolylsulphonyl)-β-cyclodextrin (67217-55-4) → Mono-3A,6A-anhydrocyclomaltoheptaose (104867-20-1) + β‐cyclodextrin (7585-39-9)

Conditions	Yield
With sodium hydroxide In water at 40℃; for 11h;	A 87.9% B 8.2%

mono-6-deoxy-6-formyl-β-cyclodextrin (159496-21-6) → β‐cyclodextrin (7585-39-9)

Conditions	Yield
With sodium tetrahydroborate In water for 24h; Ambient temperature;	72%
With sodium tetrahydroborate In methanol; water for 1h;

mono-6-deoxy-6-(p-tolylsulphonyl)-β-cyclodextrin (67217-55-4) → 6(I)-amino-6(I)-deoxycyclomaltoheptaose (29390-67-8) + β‐cyclodextrin (7585-39-9)

Conditions	Yield
With ammonia In water at 60℃; for 5h; Product distribution / selectivity;	A 70% B 30%

C42H70O35*C37H47N3(2+)*2Br(1-) (141484-64-2) → C37H47N3(2+)*2Br(1-) (141484-62-0) + β‐cyclodextrin (7585-39-9)

Conditions	Yield
In water-d2 at 30℃; Equilibrium constant; Thermodynamic data; other temperatures; free energy of activation at 70 deg C;

C42H70O35*C6H13N3OS → 3-t-butyl-1-methyl-1-nitrosothiourea (95598-14-4) + β‐cyclodextrin (7585-39-9)

Conditions	Yield
With acetate buffer at 37℃; Rate constant; dissociation constant and catalyzed rate constant of the inclusion complex is determined;

C42H70O35*C12H14N2 (114987-36-9) → β‐cyclodextrin (7585-39-9) + 1,1'-dimethyl-1,1'-dihydro-4,4'-bipyridyl (25128-26-1)

Conditions	Yield
In water at 25℃; Equilibrium constant;

6-O-α-D-maltotriosyl-β-cyclodextrin (104723-62-8) → maltotriose (6401-81-6, 17659-52-8, 19141-16-3, 20702-55-0, 52485-13-9, 69429-19-2, 80446-86-2, 80446-87-3, 94799-30-1, 94799-74-3, 113158-51-3, 118396-93-3, 121153-20-6, 133267-59-1, 1109-28-0, 142185-35-1) + β‐cyclodextrin (7585-39-9)

Conditions	Yield
With isoamylase Product distribution; hydrolysis;

prostacyclin*β-cyclodextrin (77164-53-5) → 7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-(S)-3-hydroxy-oct-1-enyl)-cyclopentyl]-6-oxo-heptanoic acid (58962-34-8) + β‐cyclodextrin (7585-39-9)

Conditions	Yield
With phosphate buffer (pH=ca. 7); water at 10 - 30℃; Thermodynamic data; Kinetics; activation parameters: ΔS(excit.), ΔG(excit.), E investigated;

C42H70O35*C21H34O5 (69377-76-0) → 6-keto-PGF1α methyl ester (63557-55-1) + β‐cyclodextrin (7585-39-9)

Conditions	Yield
With phosphate buffer (pH=ca. 7); water at 10 - 30℃; Thermodynamic data; Kinetics; activation parameters: ΔS(excit.), ΔG(excit.), E investigated;

C42H70O35*C15H17BrNO(1+)*Br(1-) (80800-15-3) → trimethylammonium bromide (80214-62-6) + β‐cyclodextrin (7585-39-9)

Conditions	Yield
With Co(NH3)6 at 25℃; Rate constant; Equilibrium constant; host-guest complexation of cyclodextrins with detergents, photoluminescence study;

C42H70O35*C19H25BrNO(1+)*Br(1-) (80800-16-4) → trimethylammonium bromide (79671-16-2) + β‐cyclodextrin (7585-39-9)

Conditions	Yield
With Co(NH3)6 at 25℃; Rate constant; Equilibrium constant; host-guest complexation of cyclodextrins with detergents, photoluminescence study;

C42H70O35*C24H35BrNO(1+)*Br(1-) (80822-21-5) → trimethylammonium bromide (79671-17-3) + β‐cyclodextrin (7585-39-9)

Conditions	Yield
With Co(NH3)6 at 25℃; Rate constant; Equilibrium constant; host-guest complexation of cyclodextrins with detergents, photoluminescence study;

6-O-α-(62-O-α-maltotriosyl)maltotriosyl-cG7 (112269-47-3) → maltotriose (6401-81-6, 17659-52-8, 19141-16-3, 20702-55-0, 52485-13-9, 69429-19-2, 80446-86-2, 80446-87-3, 94799-30-1, 94799-74-3, 113158-51-3, 118396-93-3, 121153-20-6, 133267-59-1, 1109-28-0, 142185-35-1) + β‐cyclodextrin (7585-39-9)

Conditions	Yield
In water Product distribution; isoamylolysis;

6A,6D-di-O-α-maltotriosyl-cG7 (112240-48-9) → maltotriose (6401-81-6, 17659-52-8, 19141-16-3, 20702-55-0, 52485-13-9, 69429-19-2, 80446-86-2, 80446-87-3, 94799-30-1, 94799-74-3, 113158-51-3, 118396-93-3, 121153-20-6, 133267-59-1, 1109-28-0, 142185-35-1) + β‐cyclodextrin (7585-39-9)

Conditions	Yield
In water Product distribution; isoamylolysis;

6-O-α-(63-O-α-maltotriosyl)maltotriosyl-cG7 (112269-46-2) → maltotriose (6401-81-6, 17659-52-8, 19141-16-3, 20702-55-0, 52485-13-9, 69429-19-2, 80446-86-2, 80446-87-3, 94799-30-1, 94799-74-3, 113158-51-3, 118396-93-3, 121153-20-6, 133267-59-1, 1109-28-0, 142185-35-1) + β‐cyclodextrin (7585-39-9)

Conditions	Yield
In water Product distribution; isoamylolysis;

C42H70O35*C6H15NO3 → triethanolamine (102-71-6) + β‐cyclodextrin (7585-39-9)

Conditions	Yield
In water at 25℃; Equilibrium constant; further temperatures;

C42H70O35*C20H15O2(1-)*Na(1+) → sodium 4-pyren-1-ylbutyrate (63442-80-8) + β‐cyclodextrin (7585-39-9)

Conditions	Yield
In water at 25℃; Equilibrium constant; Thermodynamic data; quenching by triethanolamine, ΔH(excit), ΔS(excit), further temperatures;

2C42H70O35*C20H15O2(1-)*Na(1+) → C42H70O35*C20H15O2(1-)*Na(1+) + β‐cyclodextrin (7585-39-9)

Conditions	Yield
In water at 25℃; Equilibrium constant; Thermodynamic data; quenching by triethanolamine, ΔH(excit), ΔS(excit), further temperatures;

β‐cyclodextrin (7585-39-9) → heptakis(6-bromo-6-deoxy)-β-cyclodextrin (53784-83-1)

Conditions	Yield
With bromine; triphenylphosphine In N,N-dimethyl-formamide at 0 - 80℃; for 15h;	100%
With tetraethylammonium bromide; 4-pyrrolidin-1-ylpyridine; ethanaminium,N-(difluoro-λ4-sulfanylidene)-N-ethyl-,tetrafluoroborate In N,N-dimethyl-formamide at 20℃; regioselective reaction;	97%
With bromine; triphenylphosphine In N,N-dimethyl-formamide at 75 - 80℃;	95%

allyl bromide (106-95-6) + β‐cyclodextrin (7585-39-9) → heptakis(2,3,6-tri-O-allyl)-β-cyclodextrin (141126-40-1)

Conditions	Yield
Stage #1: β‐cyclodextrin With sodium hydride In N,N-dimethyl-formamide at 60℃; for 2.5h; Stage #2: allyl bromide In N,N-dimethyl-formamide at 60℃; for 16h; Further stages.;	100%
Stage #1: β‐cyclodextrin With sodium hydride In N,N-dimethyl-formamide; mineral oil at 0 - 5℃; for 1h; Stage #2: allyl bromide In N,N-dimethyl-formamide; mineral oil at 0 - 20℃;	98%
Stage #1: β‐cyclodextrin With sodium hydride In N,N-dimethyl-formamide; mineral oil at 20℃; for 0.5h; Inert atmosphere; Stage #2: allyl bromide In N,N-dimethyl-formamide; mineral oil at 20℃; Inert atmosphere;	88%
With sodium hydride In N,N-dimethyl-formamide at 20 - 23℃; for 13h;	49%

fenchene (471-84-1, 2623-54-3, 7378-37-2, 116724-26-6) + β‐cyclodextrin (7585-39-9) → β-CD-fenchene

Conditions	Yield
Stage #1: fenchene; β‐cyclodextrin In 1,4-dioxane; water at 20℃; for 0.25h; Stage #2: In water at 20 - 75℃;	100%

C23H28B10N4OPt(2+)*2NO3(1-) + β‐cyclodextrin (7585-39-9) → C23H28B10N4OPt(2+)*2NO3(1-)*C42H70O35

Conditions	Yield
In water for 0.5h; Sonication;	100%

C23H28B10N4OPt(2+)*2NO3(1-) + β‐cyclodextrin (7585-39-9) → C23H28B10N4OPt(2+)*2NO3(1-)*C42H70O35

Conditions	Yield
In water for 0.5h; Sonication;	100%

C23H28B10N4OPt(2+)*2NO3(1-) + β‐cyclodextrin (7585-39-9) → C23H28B10N4OPt(2+)*2NO3(1-)*C42H70O35

Conditions	Yield
In water for 0.5h; Sonication;	100%

C23H28B10N4OPt(2+)*2NO3(1-) + β‐cyclodextrin (7585-39-9) → C23H28B10N4OPt(2+)*2NO3(1-)*C42H70O35

Conditions	Yield
In water for 0.5h; Sonication;	100%

C23H28B10N4OPt(2+)*2NO3(1-) + β‐cyclodextrin (7585-39-9) → C23H28B10N4OPt(2+)*2NO3(1-)*C42H70O35

Conditions	Yield
In water for 0.5h; Sonication;	100%

C23H28B10N4OPt(2+)*2NO3(1-) + β‐cyclodextrin (7585-39-9) → C23H28B10N4OPt(2+)*2NO3(1-)*C42H70O35

Conditions	Yield
In water for 0.5h; Sonication;	100%

C23H28B10N4OPt(2+)*2NO3(1-) + β‐cyclodextrin (7585-39-9) → C23H28B10N4OPt(2+)*2NO3(1-)*C42H70O35

Conditions	Yield
In water for 0.5h; Sonication;	100%

[Pt((S)-(1,7-closo-carboran-1-yl)pyrid-3-ylmethanol)2(1,10-phenanthroline)](NO3)2 + β‐cyclodextrin (7585-39-9) → [Pt((S)-(1,7-closo-carboran-1-yl)pyrid-3-ylmethanol)2(1,10-phenanthroline)(β-cyclodextrin)2](NO3)2

Conditions	Yield
In water for 0.5h; Sonication;	100%

[Pt((S)-(1,12-closo-carboran-1-yl)pyrid-4-ylmethanol)2(1,10-phenanthroline)](NO3)2 + β‐cyclodextrin (7585-39-9) → [Pt((S)-(1,12-closo-carboran-1-yl)pyrid-4-ylmethanol)2(1,10-phenanthroline)(β-cyclodextrin)2](NO3)2

Conditions	Yield
In water for 0.5h; Sonication;	100%

[Pt((R)-(1,7-closo-carboran-1-yl)pyrid-4-ylmethanol)2(1,10-phenanthroline)](NO3)2 + β‐cyclodextrin (7585-39-9) → [Pt((R)-(1,7-closo-carboran-1-yl)pyrid-4-ylmethanol)2(1,10-phenanthroline)(β-cyclodextrin)2](NO3)2

Conditions	Yield
In water for 0.5h; Sonication;	100%

[Pt((S)-(1,7-closo-carboran-1-yl)pyrid-4-ylmethanol)2(1,10-phenanthroline)](NO3)2 + β‐cyclodextrin (7585-39-9) → [Pt((S)-(1,7-closo-carboran-1-yl)pyrid-4-ylmethanol)2(1,10-phenanthroline)(β-cyclodextrin)2](NO3)2

Conditions	Yield
In water for 0.5h; Sonication;	100%

[Pt((R)-(1,7-closo-carboran-1-yl)pyrid-3-ylmethanol)2(1,10-phenanthroline)](NO3)2 + β‐cyclodextrin (7585-39-9) → [Pt((R)-(1,7-closo-carboran-1-yl)pyrid-3-ylmethanol)2(1,10-phenanthroline)(β-cyclodextrin)2](NO3)2

Conditions	Yield
In water for 0.5h; Sonication;	100%

benzyl chloride (100-44-7) + β‐cyclodextrin (7585-39-9) → 2,3,6-Tri-O-benzyl-β-cyclomaltoheptaose (129318-82-7, 130322-65-5, 130322-67-7)

Conditions	Yield
With sodium hydride In dimethyl sulfoxide at 20℃; for 22h; Inert atmosphere; Schlenk technique;	99%
With sodium hydride In dimethyl sulfoxide; mineral oil at 20℃; Inert atmosphere;	96%
With sodium hydride In dimethyl sulfoxide	95%

3,4,5,6-tetrahydro-2H-pyran-2-one (542-28-9) + β‐cyclodextrin (7585-39-9) → polymer; monomer(s): β-cyclodextrin; δ-valerolactone

Conditions	Yield
at 100℃; for 48h;	98%

acetic anhydride (108-24-7) + β‐cyclodextrin (7585-39-9) → per-O-acetylated β-cyclodextrin

Conditions	Yield
With copper(II) perchlorate hexahydrate In neat (no solvent) at 20℃; for 0.25h; Inert atmosphere;	98%

1,1,1,3,3,3-hexamethyl-disilazane (999-97-3) + β‐cyclodextrin (7585-39-9) → heptakis(2,6-di-O-trimethylsilyl)cyclomaltoheptaose

Conditions	Yield
With trimethylsilyl trifluoromethanesulfonate In dichloromethane at 20℃; for 0.25h; Inert atmosphere; regioselective reaction;	97%
With iodine at 20℃; Neat (no solvent); Air atmosphere;	96%

C20H20N2*2ClH + ClH*C17H16N4 (1427351-20-9) + cucurbituril (80262-44-8) + β‐cyclodextrin (7585-39-9) → C54H52N10*C42H70O35*2C36H36N24O12*4ClH

Conditions	Yield
In water at 60℃; for 0.5h; Huisgen Cycloaddition;	97%

2CBP·2Cl + N-(3,5-dimethoxybenzyl)propargylammonium chloride + cucurbituril (80262-44-8) + β‐cyclodextrin (7585-39-9) → C42H52N10O4*4ClH*C42H70O35*2C36H36N24O12

Conditions	Yield
In water at 20℃; for 1h;	97%

1-(2-ethoxyethyl)-4-(pentyn-1-yl)-4-benzoyloxypiperidine oxalate + β‐cyclodextrin (7585-39-9) → C42H70O35*C21H29NO3*C2H2O4

Conditions	Yield
In ethanol; water	97%

ketoconazole (65277-42-1, 72093-26-6, 79156-75-5, 83374-59-8, 142128-57-2, 142128-58-3, 142128-59-4, 142128-60-7) + β‐cyclodextrin (7585-39-9) → C26H28Cl2N4O4*C42H70O35

Conditions	Yield
In ethanol; water at 25℃;	96.3%

4-(cyclopropylethynyl)-1-(2-ethoxyethyl)-4-(propionyloxy)piperidine + β‐cyclodextrin (7585-39-9) → β-cyclodextrin

Conditions	Yield
In ethanol; water at 50 - 55℃;	96.3%

tert-butyldimethylsilyl chloride (18162-48-6) + β‐cyclodextrin (7585-39-9) → heptakis(6-O-tert-butyldimethylsilyl)-β-cyclodextrin (123155-03-3)

Conditions	Yield
With pyridine at 20℃; for 18.6667h; Inert atmosphere;	96%
With pyridine 1) ice bath, 6.5 h; 2) 18 h, rt;	95%
With pyridine	90%

acetic anhydride (108-24-7) + β‐cyclodextrin (7585-39-9) → peracetylated β-cyclodextrin (23739-88-0)

Conditions	Yield
With iodine at 20℃; for 24h; neat (no solvent);	96%
With 1,4-diaza-bicyclo[2.2.2]octane at 55℃; for 4.5h; Neat (no solvent);	96%
With lithium perchlorate for 50h; Heating;	93%

Upstream product

• 50-99-7 D(+)-Glucose 
• 9054-89-1 Superoxide dismutase 
• 9004-53-9 Dextrin 
• 9000-90-2 alpha-Amylase 
• 9005-82-7 AMYLOSE 

Downstream Products

• 10016-20-3 Cyclohexapentylose 
• 874807-57-5 MONASCUS RED 
• 17465-86-0 Cyclooctapentylose 

Recommend Products

• 56003-42-0  4-carboxy-2-nitrophenyl butanoate 
• 58962-34-8  7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-(S)-3-hydroxy-oct-1-enyl)-cyclopentyl]-6-oxo-heptanoic acid 
• 77164-53-5  prostacyclin*β-cyclodextrin 
• 67217-55-4  6^I-O-(4-methylbenzenesulfonyl)-β-cyclodextrin 
• 7585-39-9  β-cyclodextrin 
• 98-59-9  p-toluenesulfonyl chloride 
• 333-20-0  potassium thioacyanate 
• 10016-20-3  alpha cyclodextrin 
• 2106-10-7  1-deoxy-1-fluoro-α-D-glucose 
• 26184-62-3  (S)-2-pentanol 
• 103928-88-7  β-cyclodextrin * L-phenylalanine 
• 63-91-2  L-phenylalanine 
• 495-78-3  3-(2-hydroxyphenyl)propionic acid 
• 1481-92-1  2-(3-hydroxypropyl)phenol